Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 2, 2013, Pages 163-169

  Capdevila, Jorge ^a   Wang, Wenhui ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Epoxyeicosatrienoic acid; hypertension; vasoactivity and kidney

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2C44; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; CYTOCHROME P450 EPOXYGENASE; EPITHELIAL SODIUM CHANNEL; EPOXYICOSATRIENOIC ACID; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; ARTERIOLE; BLOOD PRESSURE REGULATION; CHANNEL GATING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; KIDNEY COLLECTING TUBULE; MEMBRANE TRANSPORT; METABOLITE; NONHUMAN; POTASSIUM INTAKE; PREGLOMERULAR ARTERIOLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SODIUM INTAKE; SODIUM TRANSPORT; VASODILATATION;

ANIMALS; ARACHIDONIC ACID; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; EPITHELIAL SODIUM CHANNELS; HUMANS; HYPERTENSION; KIDNEY; MICE; MICE, TRANSGENIC; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS; SIGNAL TRANSDUCTION; SODIUM; VASODILATION;

EID: 84873566575     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835d911e     Document Type: Review

References (40)

1. Guengerich F. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8:E101-E111.
2. McGiff JC, Quilley J. 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Hypertension 2001; 10:231-237.
3. Roman RJ. P450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
4. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci 2006; 111:21-34.
5. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int 2007; 72:683-689.
6. Makita K, Takahashi K, Karara A, et al. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994; 94:2414-2420.
7. Tsao CC, Coulter SJ, Chien A, et al. Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio-and stereoselective products. J Pharmacol Exp Ther 2001; 299:39-47.
8. DeLozier TC, Tsao CC, Coulter SJ, et al. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 2004; 310:845-854.
9. Nakagawa K, Holla VR, Wei Y, et al. Salt sensitive hypertension is associated with a dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 2006; 116:1696-1702.
10. Zeldin DC, Foley J, Ma J, et al. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996; 50:1111-1117.
11. Lasker JM, Chen WB, Wolf I, et al. Formation of 20- hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. J Biol Chem 2000; 275:4118-4126.
12. Athirakul K, Bradbury JA, Graves JP, et al. Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J 2008; 22:4096-4108.
13. Wei Y, Lin DH, Kemp R, et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 2004; 124:719-727.
14. Sun P, Lin DH, Yue P, et al. High potassium intake enhances the inhibitory effect of 11,12-EET on ENaC. J Am Soc Nephrol 2010; 21:1667-1677.
15. Sun P, Lin DH, Wang T, et al. Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC. Am J Physiol Renal Physiol 2006; 291:1192-1200.
16. Pavlov TS, Ilatovskaya DV, Levchenko V, et al. Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Renal Physiol 2011; 301:F672-F681.
17. Siragy HM, Linden J. Sodium intake markedly alters renal interstitial fluid adenosine. Hypertension 1996; 27:404-407.
18. Sun P, Liu W, Lin DH, et al. Epoxyeicosatrienoic acid (EET) activates the Ca2\+-dependent big conductance K channel in the cortical collecting duct. J Am Soc Nephrol 2009; 20:513-523.
19. Wang Z, Wei Y, Falck JR, et al. Arachidonic acid inhibits basolateral K channels in the cortical collecting duct via cytochrome P-450 epoxygenasedependent metabolic pathways. Am J Physiol Renal Physiol 2008; 294:F1441-F1447.
20. Satlin LM. Developmental regulation of expression of renal potassium secretory channels. Curr Opin Nephrol Hypertens 2004; 13:445-450.
21. Carroll MA. Role of the adenosine2A receptor-epoxyeicosatrienoic acid pathway in the development of salt-sensitive hypertension. Prostaglandins Other Lipid Mediat 2012; 98:39-47.
22. Imig JD, Falck JR, Wei S, et al. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res 2001; 38:247-255.
23. Imig JD, Dimitropoulou C, Reddy DS, et al. Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2 \+-activated K\+ channels. Microcirculation 2008; 15:137-150.
24. Tian L, Duncan RR, Hammond MSL, et al. Alternative splicing switches potassium channel sensitivity to protein phosphorylation. J Biol Chem 2001; 276:7717-7720.
25. Zhou X, Wulfsen I, Korth M, et al. Palmitoylation and membrane association of the stress axis regulated insert (STREX) controls BK channel regulation by protein kinase C. J Biol Chem 2012; 287:32161-32171.
26. Holla VR, Adas F, Imig JD, et al. Alterations in the regulation of androgensensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 2001; 98:5211-5216.
27. Ma J, Qu W, Scarborough PE, et al. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem 1999; 274:17777-17788.
28. Sun P, Antoun J, Lin DH, et al. Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hypertension 2012; 59:339-347.
29. Zhao X, Pollock DM, Zeldin DC, et al. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension 2003; 42:775-780.
30. Elmarakby AA, Quigley JE, Pollock DM, et al. Tumor necrosis factor {alpha} blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 2006; 47:557-562.
31. Garty H. Mechanisms of aldosterone action in tight epithelia. J Membrane Biol 1986; 90:193-205.
32. Doucet A, Katz AI. Short-term effect of aldosterone on Na-K-ATPase in single nephron segments. Am J Physiol 1981; 241:273-278.
33. Palmer LG, Frindt G. Regulation of apical membrane Na and K channels in rat renal collecting tubules by aldosterone. Semin Nephrol 1992; 12:37-43.
34. Lee CR, Imig JD, Edin ML, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertensioninduced renal injury in mice. FASEB J 2010; 24:3770-3781.
35. Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997; 272:12551-12559.
36. Zordoky BNM, El-Kadi AOS. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010; 125:446-463.
37. Bellien J, Joannides R. Epoxyeicosatrienoic acid pathway in human health and diseases. J Cardiovasc Pharmacol 2012. [Epub ahead of print]
38. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
39. King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 2005; 15:7-13.
40. Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348: 57-61.